source
- Eli Lilly to file FDA application for obesity drug retatrutide after Phase 3 trial resultsEli Lilly announced that two additional Phase 3 trials of its experimental obesity medicine retatrutide met their primary goals, and the company plans to submit an FDA application for the drug next…
- Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trialEli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…